Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LY2940680

Known as: LY-2940680 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

PhthalazinesTaladegib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma
Purpose: The purpose of this study was to determine a recommended phase II dose and schedule of LY2940680 (taladegib) for safe… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2017
2017
A structurally guided dissection-then-evolution strategy for ligand optimization of smoothened receptor† †The authors declare no competing interests. ‡ ‡Electronic supplementary information (ESI…
We present herein a novel dissection-then-evolution strategy for ligand optimization. 
  • figure 1
  • table 1
  • figure 2
2016
2016
Pharmacological evaluation of a series of smoothened antagonists in signaling pathways and after topical application in a depilated mouse model
The Hedgehog (HH) pathway has been linked to the formation of basal cell carcinoma (BCC), medulloblastoma, and other cancers. The… Expand
Review
2015
Review
2015
Molecular Pathways: Novel Approaches for Improved Therapeutic Targeting of Hedgehog Signaling in Cancer Stem Cells
The Hedgehog (Hh) signaling pathway is critical for embryonic development. In adult tissues, Hh signaling is relatively quiescent… Expand
  • figure 1
  • table 1
  • figure 2
2015
2015
Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures
We investigated the sensitivity of intrahepatic cholangiocarcinoma (IHCCA) subtypes to chemotherapeutics and molecular targeted… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
2015
2015
MRT‐92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor
The Smoothened (Smo) receptor, a member of class F G protein‐coupled receptors, is the main transducer of the Hedgehog (Hh… Expand
2015
2015
Abstract B32: LY2940680, a hedgehog (Hh) pathway inhibitor, demonstrates anti-tumor activity in patients with advanced basal cell carcinoma (BCC)
We previously reported interim dose escalation results from this multi-center, open-label Phase 1 clinical trial (NCT01226485… Expand
Review
2014
Review
2014
Emerging drugs and combination strategies for basal cell carcinoma
Introduction: Basal cell carcinoma (BCC) is a malignancy that is driven by an activated Hedgehog (Hh) pathway. Smoothened… Expand
2014
2014
Molecular modeling study on the dynamical structural features of human smoothened receptor and binding mechanism of antagonist LY2940680 by metadynamics simulation and free energy calculation.
BACKGROUND The smoothened (SMO) receptor, one of the Class F G protein coupled receptors (GPCRs), is an essential component of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2013
Highly Cited
2013
Structure of the human smoothened receptor bound to an antitumour agent
The smoothened (SMO) receptor, a key signal transducer in the hedgehog signalling pathway, is responsible for the maintenance of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE